| Risk | Moderately High |
|---|---|
| Min SIP Amount | ₹1000 |
| Expense Ratio | 0.57% |
| NAV | ₹65.20 (27 Oct 2020) |
|---|---|
| Fund Started | 07 Jan 2013 |
| Fund Size | ₹13 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Sumitomo Chemical India Pvt. Ltd. | Others | Equity | 8.9% |
| Adani Enterprises Ltd. | Services | Equity | 8.1% |
| PI Industries Ltd. | Chemicals | Equity | 7.6% |
| Stylam Industries Ltd. | FMCG | Equity | 7.3% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | Equity | 7.1% |
| Ajanta Pharma Ltd. | Healthcare | Equity | 6.6% |
| Aarti Industries Ltd. | Chemicals | Equity | 6.3% |
| Majesco Ltd. | Technology | Equity | 6.1% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 5.6% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 5.1% |
Quant Mid Cap Fund Direct Growth is a Hybrid Mutual Fund Scheme launched by Quant Mutual Fund. This scheme was made available to investors on 07 Jan 2013. Sanjeev Sharma is the Current Fund Manager of Quant Mid Cap Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹13 Cr and the Latest NAV as of 27 Oct 2020 is ₹65.20.
The Quant Mid Cap Fund Direct Growth is rated Moderately High risk. Minimum SIP Investment is set to 1000. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year
The scheme aims at providing long term capital appreciation and generating income with a diversified portfolio of Mid Cap companies.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.